Advanced HCC spans 10-20% of HCC diagnoses, and is associated with poor outcomes. This session will focus on fundamental aspects of advanced HCC management relevant to IRs in practice, and the potential role of Precision Medicine initiatives in developing and improving treatments for this disease. This course is designed to education and update IRs in advanced HCC epidemiology, classification, medical and locoregional therapy, and the evolving role for precision medicine in advanced HCC treatment.

This enduring activity is designed to meet the educational needs of interventional radiologists, IRs in training, nurses, physician assistants and other physicians at all levels with special interest in oncologic interventions, embolization and HCC.

Learning Objectives

Upon completion of this activity, participants should be able to:

• Understand the benefits and limitations of the current HCC staging systems including the ECOG system.
• Describe the advantages and limitations of the IA and systemic therapies.
• Identify the alternatives for HCC with PVT.

Faculty Information

Coordinator
Ron C. Gaba, MD, FSIR; University of Illinois Hospital
Regina Schwind; University of Illinois at Chicago

Speakers
Carl Schmidt, MD, FACS; The Ohio State University
Anthony B. El-Khoueiry, MD; Keck Medicine of USC Norris Cancer Center
Daniel B. Brown, MD, FSIR; Vanderbilt University Medical Center
Alda L. Tam, MD; MD Anderson Cancer Center